{"id":10610,"date":"2026-01-30T15:22:52","date_gmt":"2026-01-30T14:22:52","guid":{"rendered":"https:\/\/neurohirurgija.in.rs\/?page_id=10610"},"modified":"2026-07-12T08:29:54","modified_gmt":"2026-07-12T06:29:54","slug":"brain-metastases","status":"publish","type":"page","link":"https:\/\/neurohirurgija.in.rs\/en\/brain-metastases\/","title":{"rendered":"Brain Metastases (Secondary Brain Tumors) \u2014 Diagnosis, Treatment &amp; Prognosis"},"content":{"rendered":"\n<div style=\"line-height:1.35; margin:0 0 18px 0;\">\n  <div>\n    <span style=\"font-weight:600;\">Author:<\/span>\n    <a href=\"https:\/\/neurohirurgija.in.rs\/en\/cv-en\/\" style=\"color:#004a80; font-weight:600; text-decoration:none;\" onmouseover=\"this.style.textDecoration='underline';\" onmouseout=\"this.style.textDecoration='none';\">\n       Dr. Zeljko Kojadinovic, MD, PhD\n    <\/a>\n    \u2014 Neurosurgeon and Pain Management Specialist\n  <\/div>\n\n  <div>\n    <span style=\"font-weight:600;\">Specialized Experience:<\/span>\n    30 years of clinical expertise in neurosurgery.\n  <\/div>\n\n  <div>\n    <span style=\"font-weight:600;\">Last medically reviewed:<\/span>\n    May 28, 2026\n  <\/div>\n<\/div>\n\n\n\n<div style=\"background:#fff7cc; border:1px solid #ffe08a; padding:12px; border-radius:8px; margin:16px 0;\">\n  <div style=\"font-weight:700; color:#5a4b00; font-size:16px; margin-bottom:6px;\">\n    <h3 id=\"who-this-brain-metastases-page-is-for\">Who This Brain Metastases Page Is For<\/h3>\n  <\/div>\n\n  <p style=\"margin:0; color:#3b2f00; line-height:1.5;\">\n    This page is intended for patients diagnosed with <strong>brain metastases (secondary brain tumors)<\/strong> and for family members seeking a clear, medically accurate explanation of what this diagnosis means in real clinical practice.\n    <br><br>\n    Readers can focus on the sections most relevant to their situation using the table of contents, including prognosis, surgical decision-making, and tumor-specific characteristics of brain metastases.\n    <br><br>\n    If surgery is being proposed or declined, prognosis appears unclear or contradictory, multiple treatment options are possible, \n    or there is uncertainty about whether local brain control will meaningfully change outcome \u2014 an individualized\n    <a href=\"https:\/\/neurohirurgija.in.rs\/en\/second-opinion-in-neurosurgery-trusted-insight\/\" target=\"_blank\" rel=\"noopener\" style=\"color:#005c99; text-decoration:underline;\">\n      neurosurgical second opinion\n    <\/a>\n    can help clarify risks, expected benefits, and the role of surgery within the overall cancer treatment strategy.\n  <\/p>\n<\/div>\n\n\n\n<div style=\"border: 1px solid #ccc; border-radius: 12px; padding: 20px; margin: 28px 0 36px; box-shadow: 0 2px 8px rgba(0,0,0,0.08); background-color: #f9f9f9;\"> \n  <h3 style=\"margin-top: 0; color: #004466;\">\n    When patients usually seek a second opinion for brain metastases\n  <\/h3>\n\n  <ul style=\"margin: 10px 0 14px 18px;\">\n    <li>Surgery is being proposed or declined, but the reasons are unclear or opinions differ between specialists<\/li>\n    <li>There is uncertainty whether neurological deterioration is caused by the metastasis itself, edema, hemorrhage, or systemic cancer progression<\/li>\n    <li>Multiple brain metastases are present, and it is unclear whether surgery, radiosurgery, or combined treatment offers the best benefit<\/li>\n    <li>A single brain metastasis is detected, but its location carries high surgical risk and alternative options are being considered<\/li>\n    <li>Brain metastases are locally controlled, yet the patient continues to deteriorate without a clear explanation<\/li>\n    <li>Prognosis estimates differ significantly between treating physicians<\/li>\n    <li>There is uncertainty about how brain treatment should be sequenced with systemic cancer therapy<\/li>\n    <li>Two neurosurgeons or oncology teams recommend different treatment strategies for the same MRI findings<\/li>\n  <\/ul>\n\n  <p style=\"margin: 0;\">\n    In these situations, an expert neurosurgical review can help clarify the role of surgery, assess realistic neurological benefit, \n    integrate brain findings with the primary cancer prognosis, and determine whether local treatment is likely to improve function or quality of life:\n    <a href=\"#request-brain-metastases-second-opinion\" style=\"font-weight: 700; text-decoration: underline;\">\n      Request Consultation\n    <\/a>\n  <\/p>\n<\/div>\n\n\n\n<div style=\"background:#f4faff; border:1px solid #cce5ff; padding:14px 16px; border-radius:12px; margin:18px 0; box-shadow:0 10px 22px rgba(0,60,120,0.06);\"> \n  <h3 id=\"brain-metastases-quick-summary\" style=\"margin:0 0 10px 0; color:#003a66; font-size:18px;\">\n    Brain Metastases \u2014 Quick Summary (Read This First)\n  <\/h3>\n\n  <ul style=\"margin:0; padding-left:18px; color:#0f172a; line-height:1.55;\">\n    <li><strong>Brain metastases are the most common brain tumors in adults.<\/strong> They occur when cancer spreads to the brain from another organ and are therefore called <em>secondary brain tumors<\/em>.<\/li>\n\n    <li><strong>Approximately 20\u201340% of patients with systemic cancer develop brain metastases<\/strong> during the course of their disease, depending on tumor type and available systemic therapy.<\/li>\n\n    <li><strong>The most common primary sources are lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer.<\/strong> In about <strong>20\u201330%<\/strong> of patients, brain metastases are diagnosed before the primary cancer is known.<\/li>\n\n    <li><strong>Neurological symptoms are often caused by edema and pressure, not tumor size alone.<\/strong> Even small metastases can cause severe symptoms due to swelling, increased intracranial pressure, hemorrhage, or obstruction of cerebrospinal fluid pathways.<\/li>\n\n    <li><strong>Local treatment (surgery or stereotactic radiosurgery) can control brain disease and improve neurological function,<\/strong> but it usually does <strong>not cure the cancer<\/strong>. Overall survival is most often determined by the biology and control of the primary tumor.<\/li>\n\n    <li><strong>Surgical decisions are individualized.<\/strong> Surgery may be appropriate for large or symptomatic lesions, for tissue diagnosis, or when rapid neurological relief is needed\u2014but the number of metastases alone does not determine operability.<\/li>\n\n    <li><strong>Different specialists may reasonably recommend different treatment plans.<\/strong> Variability reflects tumor biology, systemic disease status, neurological risk, and available treatment options rather than medical error.<\/li>\n\n    <li><strong>Patients may deteriorate or die even when all visible brain metastases are controlled.<\/strong> This can result from microscopic systemic spread, new CNS seeding, leptomeningeal disease, paraneoplastic syndromes, thrombosis, infection, or metabolic failure.<\/li>\n\n    <li><strong>This page is structured so you can read only what matters to you.<\/strong> Use the Contents box to jump to sections on symptoms, diagnosis, treatment options, prognosis, or when a neurosurgical second opinion is important.<\/li>\n  <\/ul>\n<\/div>\n\n<p style=\"margin:8px 0 0 0; color:#334155; font-size:14px; line-height:1.5;\">\n  Most readers benefit from the Quick Summary plus the sections on <strong>How Brain Metastases Cause Symptoms<\/strong>, <strong>Treatment Strategy<\/strong>, and <strong>Prognosis<\/strong>. Other sections provide deeper clinical context and decision-making insight.\n<\/p>\n\n\n\n<style>\n\/* ===== BRAIN METASTASIS TOC (Blue Accordion) ===== *\/\n.ptns-toc-simple {\n  max-width: 420px;\n  margin: 0 0 22px 0;\n  font-family: system-ui, -apple-system, \"Segoe UI\", Roboto, Arial, sans-serif;\n}\n.ptns-toc-simple .card {\n  background: #f4faff;\n  border: 1px solid #cce5ff;\n  border-radius: 12px;\n  padding: 14px;\n  box-shadow: 0 10px 22px rgba(0,60,120,0.06);\n}\n.ptns-toc-simple summary {\n  list-style: none;\n  cursor: pointer;\n  display: flex;\n  align-items: center;\n  justify-content: space-between;\n}\n.ptns-toc-simple summary::-webkit-details-marker { display:none; }\n.ptns-toc-simple .title {\n  font-weight: 800;\n  font-size: 22px;\n  color: #003a66;\n  margin: 0;\n}\n.ptns-toc-simple summary::after {\n  content: \"\u25b8 Show\";\n  font-weight: 700;\n  color: #005c99;\n  border: 1px solid #cce5ff;\n  padding: 6px 10px;\n  border-radius: 6px;\n  font-size: 13px;\n}\n.ptns-toc-simple details[open] summary::after { content: \"\u25be Hide\"; }\n\n.ptns-toc-simple ul {\n  margin: 12px 0 0 0;\n  padding: 0;\n  list-style: none;\n}\n.ptns-toc-simple li {\n  position: relative;\n  padding-left: 26px;\n  margin: 10px 0;\n  font-size: 15px;\n}\n.ptns-toc-simple li::before {\n  content: \"\";\n  width: 7px;\n  height: 7px;\n  border-radius: 50%;\n  background: #005c99;\n  position: absolute;\n  left: 8px;\n  top: 8px;\n}\n.ptns-toc-simple .sub-item {\n  padding-left: 42px;\n}\n.ptns-toc-simple .sub-item::before {\n  left: 24px;\n}\n.ptns-toc-simple a {\n  color: #005c99;\n  text-decoration: none;\n  font-weight: 700;\n}\n.ptns-toc-simple a:hover {\n  text-decoration: underline;\n}\n<\/style>\n\n<div class=\"ptns-toc-simple\" aria-label=\"Table of contents\">\n  <div class=\"card\">\n    <details>\n      <summary>\n        <h3 class=\"title\">Contents<\/h3>\n      <\/summary>\n\n      <ul>\n        <!-- Top blocks -->\n        <li><a href=\"#who-this-brain-metastases-page-is-for\">Who this page is for<\/a><\/li>\n        <li><a href=\"#when-patients-usually-seek-a-second-opinion-for-brain-metastases\">When to seek consult<\/a><\/li>\n        <li><a href=\"#brain-metastases-quick-summary\">Quick summary<\/a><\/li>\n\n        <!-- Definition & origin -->\n        <li style=\"margin-top:14px;\"><a href=\"#definition\">What is brain metastasis<\/a><\/li>\n        <li><a href=\"#origin\">Where it comes from<\/a><\/li>\n        <li><a href=\"#why-different-from-primary-brain-tumors\">Why it is different<\/a><\/li>\n\n        <!-- Location & mechanisms -->\n        <li style=\"margin-top:14px;\"><a href=\"#location\">Brain locations<\/a><\/li>\n        <li><a href=\"#how-metastasis-damage-brain\">How it harms brain<\/a><\/li>\n        \n        <!-- Why death despite control -->\n        <li style=\"margin-top:14px;\"><a href=\"#why-death-even-when-no-more-metastases-are-detectable\">Why death can occur<\/a><\/li>\n       \n\n        <!-- Symptoms & diagnosis -->\n        <li style=\"margin-top:14px;\"><a href=\"#symptoms\">Symptoms<\/a><\/li>\n        <li><a href=\"#diagnostic-workup\">Diagnosis<\/a><\/li>\n        <li><a href=\"#when-primary-tumor-not-known\">Unknown primary<\/a><\/li>\n\n        <!-- Surgery decisions -->\n        <li style=\"margin-top:14px;\"><a href=\"#how-neurosurgeons-decide-on-surgery-for-brain-metastases\">Surgery decisions<\/a><\/li>\n        <li class=\"sub-item\"><a href=\"#number-of-metastases-is-not-the-only-criterium-for-surgery\">Count is not enough<\/a><\/li>\n        <li class=\"sub-item\"><a href=\"#why-two-neurosurgeons-two-opinions\">Why opinions differ<\/a><\/li>\n\n        <!-- Treatment overview -->\n        <li style=\"margin-top:14px;\"><a href=\"#multidisciplinary-approach\">Team-based planning<\/a><\/li>\n        <li><a href=\"#treatment--modalities\">Treatment options<\/a><\/li>\n        <li class=\"sub-item\"><a href=\"#symptomatic-treatment\">Symptom control<\/a><\/li>\n        <li class=\"sub-item\"><a href=\"#surgical-treatment\">Surgery<\/a><\/li>\n\n        <!-- Radiotherapy -->\n        <li style=\"margin-top:14px;\"><a href=\"#radiotherapy\">Radiotherapy<\/a><\/li>\n        \n        <!-- Systemic therapy -->\n        <li style=\"margin-top:14px;\"><a href=\"#chemotherapy\">Systemic therapy- Chemo and Immunotherapy<\/a><\/li>\n  <li style=\"margin-top:14px;\"><a href=\"#recurrent-metastases\">Recurrent metastases treatment<\/a><\/li>\n\n        <!-- CTA -->\n        <li style=\"margin-top:14px;\"><a href=\"#request-brain-metastases-second-opinion\">Request consultation<\/a><\/li>\n\n        <!-- Prognosis -->\n        <li style=\"margin-top:14px;\"><a href=\"#prognosis\">Prognosis<\/a><\/li>\n        \n        <!-- Tumor-specific sections -->\n        <li style=\"margin-top:14px;\"><a href=\"#lung-cracinoma\">Lung cancer<\/a><\/li>\n        <li><a href=\"#breast-carcinoma\">Breast cancer Brain Metastases<\/a><\/li>\n        <li><a href=\"#melanoma\">Melanoma Brain Metastases<\/a><\/li>\n        <li><a href=\"#renal-cell-carcinoma\">Renal cell carcinoma Brain Metastases<\/a><\/li>\n        <li><a href=\"#colorectal-cancer\">Colorectal cancer Brain Metastases<\/a><\/li>\n        <li><a href=\"#unknown-primary-tumor\">Brain Metastases from an Unknown Primary<\/a><\/li>\n\n        <!-- FAQ -->\n        <li style=\"margin-top:14px;\"><a href=\"#faq-brain-metastasis\">FAQs<\/a><\/li>\n      <\/ul>\n    <\/details>\n  <\/div>\n<\/div>\n\n<style>\nh2, h3 { scroll-margin-top: 110px; }\n<\/style>\n\n\n\n<h2 id=\"definition\" class=\"wp-block-heading\">What Are Brain Metastases?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastases are <strong>the most common type of brain tumors in adults<\/strong>. They occur when cancer cells spread to the brain from a malignant tumor elsewhere in the body. For this reason, brain metastases are also called <strong>secondary brain tumors<\/strong>, in contrast to primary brain tumors that originate from brain tissue itself.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is estimated that <strong>20\u201340% of all patients with systemic cancer will develop brain metastases during the course of their disease<\/strong>, depending on the primary tumor type and advances in systemic therapy. As cancer survival improves, the incidence of brain metastases continues to rise.<\/p>\n\n\n\n<h3 id=\"origin\" class=\"wp-block-heading\">Where Do Brain Metastases Come From?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastases most commonly originate from the following primary cancers:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lung cancer<\/strong> \u2013 approximately <strong>40\u201350%<\/strong> of all brain metastases<\/li>\n\n\n\n<li><strong>Breast cancer<\/strong> \u2013 approximately <strong>15\u201325%<\/strong><\/li>\n\n\n\n<li><strong>Melanoma<\/strong> \u2013 approximately <strong>5\u201320%<\/strong> (with a particularly high biological tendency to spread to the brain)<\/li>\n\n\n\n<li><strong>Renal cell carcinoma<\/strong> \u2013 approximately <strong>5\u201310%<\/strong><\/li>\n\n\n\n<li><strong>Colorectal cancer<\/strong> \u2013 approximately <strong>3\u20135%<\/strong><\/li>\n\n\n\n<li>Other cancers (including ovarian, bladder, head and neck, and unknown primaries) account for a smaller proportion<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In <strong>20\u201330% of patients<\/strong>, brain metastases are diagnosed <strong>before the primary cancer is known<\/strong>. In these cases, the brain lesion may be the first manifestation of an underlying systemic malignancy, and further diagnostic workup is required to identify the site of origin.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"819\" height=\"454\" src=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastasis.jpg\" alt=\"Brain metastasis originating from lung cancer\" class=\"wp-image-10636\" style=\"aspect-ratio:1.8040268456375839;width:676px;height:auto\" srcset=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastasis.jpg 819w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastasis-300x166.jpg 300w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastasis-768x426.jpg 768w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastasis-18x10.jpg 18w\" sizes=\"auto, (max-width: 819px) 100vw, 819px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Image: Brain metastasis originating from lung cancer<\/strong><\/p>\n\n\n\n<h3 id=\"why-different-from-primary-brain-tumors\" class=\"wp-block-heading\">Why Brain Metastases Are Different from Primary Brain Tumors<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastases behave differently from primary <a href=\"https:\/\/neurohirurgija.in.rs\/en\/brain-tumors\/\">brain tumors<\/a> because they represent <strong>systemic cancer involvement of the brain<\/strong>, not a disease limited to the central nervous system. Even when brain metastases are successfully removed or controlled locally, the <strong>underlying malignant disease elsewhere in the body often continues to determine overall prognosis<\/strong>.<\/p>\n\n\n\n<h2 id=\"location\" class=\"wp-block-heading\">Hematogenous Spread and Brain Location<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastases most commonly reach the brain through <strong>hematogenous spread<\/strong>. Tumor cells circulate systemically and tend to lodge at the <strong>gray\u2013white matter junction<\/strong>, where abrupt changes in vessel diameter slow blood flow and facilitate tumor cell deposition. This explains why metastases are frequently located in the cerebral hemispheres and why they often appear as well-demarcated lesions surrounded by extensive edema.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the time of diagnosis, approximately <strong>60\u201370% of patients have multiple brain metastases<\/strong>, while <strong>30\u201340% present with a single lesion<\/strong>. This high rate of multiplicity reflects the systemic nature of malignant disease and distinguishes brain metastases from most primary brain tumors, which are usually solitary at presentation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The anatomical distribution of brain metastases follows regional cerebral blood flow. About <strong>80%<\/strong> are located in the <strong>cerebral hemispheres<\/strong>, <strong>15\u201320%<\/strong> in the <strong>cerebellum<\/strong>, and <strong>3\u20135%<\/strong> in the <strong>brainstem<\/strong>. In adults, <strong>metastasis is the most common malignant lesion of the cerebellum<\/strong>. For this reason, when an enhancing lesion is detected in the cerebellum on MRI, <strong>metastatic disease must be excluded first<\/strong>, even in patients without a known primary cancer.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"how-metastasis-damage-brain\" class=\"wp-block-heading\">How Brain Metastases Develop and Damage the Brain<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Why Small Metastases Can Cause Severe Symptoms<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Once metastatic cells establish themselves within the brain, they disrupt the blood\u2013brain barrier, causing fluid to leak from the vessels into the surrounding tissue. This results in <strong>vasogenic <a href=\"https:\/\/neurohirurgija.in.rs\/en\/brain-edema-explained\/\">edema<\/a><\/strong>, which creates a cascade of damage: the swelling physically pushes brain cells away from their capillary blood supply and compresses small vessels, severely impairing local circulation and nutrient delivery. Because the brain is enclosed within the <strong>rigid, unyielding skull<\/strong>, this expanding edema quickly leads to a rise in <strong><a href=\"https:\/\/neurohirurgija.in.rs\/en\/intracranial-pressure-icp-explained\/\">intracranial pressure (ICP)<\/a><\/strong>. As the pressure builds, the tumor and edema can push the brain\u2019s delicate structures across the center line (<strong><a href=\"https:\/\/neurohirurgija.in.rs\/en\/mass-effect-midline-shift-brain-herniation-explained\/\">midline shift<\/a><\/strong>) or force them into narrow openings in the skull, a life-threatening process known as <strong>herniation<\/strong> that can lead to sudden coma or death. This elevated pressure further compromises global brain circulation, creating a dangerous cycle of oxygen deprivation and tissue dysfunction. In tight spaces like the <strong>posterior fossa<\/strong>, even a small metastasis can cause rapid neurological collapse by compressing the brainstem or obstructing cerebrospinal fluid pathways, leading to acute <a href=\"https:\/\/neurohirurgija.in.rs\/en\/acute-hydrocephalus-explained\/\">hydrocephalus<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These mechanisms explain why patients may deteriorate rapidly and why symptom control often requires urgent intervention.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Increased Intracranial Pressure (ICP)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">As edema and mass effect increase, <strong>intracranial pressure (ICP)<\/strong> may rise. Elevated ICP can lead to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>worsening headache<\/li>\n\n\n\n<li>nausea and vomiting<\/li>\n\n\n\n<li>reduced level of consciousness<\/li>\n\n\n\n<li>life-threatening brain herniation if untreated<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This is one of the reasons why symptomatic brain metastases often require <strong>immediate local treatment<\/strong>, regardless of the long-term oncological plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Hemorrhage and Acute Neurological Deterioration<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Some metastases\u2014particularly those from <strong>melanoma, renal cell carcinoma, choriocarcinoma, and certain lung cancers<\/strong>\u2014have a strong tendency to bleed. Intratumoral hemorrhage can cause sudden neurological decline and may convert a previously stable situation into a neurosurgical emergency.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Systemic and Immune-Mediated Effects<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Neurological dysfunction in cancer patients is not always caused directly by visible metastases. Immune-mediated processes or systemic complications\u2014such as metabolic failure, infections, or treatment toxicity\u2014can significantly worsen brain function. (See the section below on <strong>Paraneoplastic Syndromes<\/strong> for more detail on how cancer affects the nervous system from a distance).<\/p>\n\n\n\n<h2 id=\"why-death-even-when-no-more-metastases-are-detectable\" class=\"wp-block-heading\">Why Patients May Die Even When Brain Metastases Are Locally Controlled<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Modern neurosurgery, stereotactic radiosurgery (Gamma Knife, CyberKnife), and radiotherapy can sometimes eliminate <strong>all visible<\/strong> brain metastases on MRI. However, local brain control does not necessarily mean the cancer has been cured, nor does it guarantee long-term survival. Major guidelines emphasize that overall outcome is often driven by the <strong>systemic disease trajectory<\/strong>, even when intracranial lesions are controlled.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1) Micrometastatic Disease and \u201cInvisible\u201d Systemic Progression<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A patient may have no large tumors detectable on routine imaging, yet still have <strong>microscopic dissemination<\/strong> (micrometastases) throughout the body. This can progressively impair organ function without forming a single \u201cdominant\u201d mass.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Examples include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>diffuse liver infiltration causing liver failure before a discrete bulky lesion is seen,<\/li>\n\n\n\n<li>bone marrow infiltration causing progressive cytopenias (anemia, infections, bleeding),<\/li>\n\n\n\n<li>lymphangitic spread in the lungs impairing oxygenation without a large lung mass.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In other words, cancer can behave as a <strong>systemic biological process<\/strong>, not only as a collection of visible tumors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2) New CNS Seeding Despite Local Control of Known Lesions<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Even if treated lesions remain controlled, the underlying systemic cancer may continue to shed tumor cells, leading to <strong>new brain metastases<\/strong> or diffuse CNS involvement over time. A 2023 analysis of causes of death in brain metastasis patients suggests that neurological decline is often linked to ongoing CNS seeding rather than failure of local growth control of the original lesions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3) Leptomeningeal Disease (LM) and Diffuse CNS Spread<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Some patients develop <strong>leptomeningeal metastasis<\/strong>, which occurs when cancer cells escape the solid tumor and spread into the <strong>meninges<\/strong> (the thin protective layers or &#8216;linings&#8217; that wrap around the brain and spinal cord) and the <strong>cerebrospinal fluid (CSF)<\/strong> that bathes them. Instead of forming a single solid lump that is easy to see on a scan, the cancer spreads like a &#8216;thin coat of paint&#8217; or a &#8216;dusting of snow&#8217; over the entire surface of the brain and its nerves. This can cause rapid neurological deterioration because the cancer cells circulate everywhere the fluid goes, potentially affecting multiple nerves at once and blocking fluid drainage. This is one of the key &#8216;hidden&#8217; reasons families experience a sudden decline; the solid tumors on previous scans may look stable or &#8216;good,&#8217; but this invisible fluid-based spread is causing new and severe damage.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4) Paraneoplastic Neurologic Syndromes (Immune-Mediated Injury)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Some neurological deterioration is not caused by tumor tissue at all, but by&nbsp;<strong>immune-mediated remote effects of cancer<\/strong>, known as paraneoplastic neurologic syndromes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These can involve:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>limbic encephalitis (confusion, seizures, memory loss),<\/li>\n\n\n\n<li>cerebellar degeneration (rapid severe ataxia),<\/li>\n\n\n\n<li>myelopathy,<\/li>\n\n\n\n<li>peripheral and autonomic neuropathies (including dangerous blood pressure\/heart rate instability).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly: paraneoplastic syndromes may occur when the cancer burden is small or not yet clearly visible, and they can progress independently of \u201ctumor size.\u201d Modern diagnostic criteria and practical management frameworks emphasize exactly this challenge.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">5) Cancer-Related Hypercoagulability (Blood Clots)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Cancer increases the risk of <strong>venous thromboembolism<\/strong> (DVT\/PE) and other thrombotic events. A patient with stable imaging can still die suddenly from pulmonary embolism or suffer disabling strokes or organ infarctions due to the prothrombotic state of malignancy. (This is one of the most common \u201cunexpected\u201d catastrophic events in oncology.)<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">6) Infections, Metabolic Failure, and Treatment-Related Toxicity<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Even without bulky tumors, patients may die from:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>severe infection\/sepsis (especially with chemotherapy-related immunosuppression or marrow involvement),<\/li>\n\n\n\n<li>renal failure, electrolyte derangements, malnutrition\/cachexia,<\/li>\n\n\n\n<li>treatment-related toxicity (systemic therapy, immunotherapy, steroid complications).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Steroids, for example, may be necessary for edema\/ICP symptom control, but they also increase risks such as infection, myopathy, diabetes, delirium, and GI complications\u2014one reason guidelines stress careful indication and tapering.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Key Message for Patients and Families<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Local brain control is extremely valuable because it can:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>prevent fatal intracranial pressure crises,<\/li>\n\n\n\n<li>reduce seizures and neurological disability,<\/li>\n\n\n\n<li>preserve independence and quality of life.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Evo ispravljenog i &#8222;ispeglanog&#8220; zavr\u0161etka te sekcije. Izbacio sam duplirane delove i spojio re\u010denice u logi\u010dan, sna\u017ean zaklju\u010dak:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Local brain control is extremely valuable because it can prevent fatal intracranial pressure crises, reduce seizures, and preserve neurological function. <strong>However, overall survival is usually determined by the behavior of the primary cancer and the extent of extracranial disease.<\/strong> Survival may still be limited by systemic cancer biology, diffuse microscopic spread, immune-mediated complications (paraneoplastic syndromes), leptomeningeal disease, thrombosis, infection, or metabolic failure. This is why brain metastasis treatment is best approached as a comprehensive multidisciplinary strategy, rather than just a &#8216;brain procedure plan.<\/p>\n\n\n\n<h2 id=\"symptoms\" class=\"wp-block-heading\">Symptoms of Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Common symptom patterns include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Headache<\/strong> (often from edema and pressure effects)<\/li>\n\n\n\n<li><strong>Seizures<\/strong><\/li>\n\n\n\n<li><strong>Focal neurological deficits<\/strong> depending on the metastasis location (weakness, speech difficulty, vision changes, imbalance)<\/li>\n\n\n\n<li><strong>Cognitive or behavioral changes<\/strong><br>Symptoms depend more on <strong>location, edema, and mass effect<\/strong> than on the primary cancer type.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"diagnostic-workup\" class=\"wp-block-heading\">Diagnostic Workup and Imaging Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Diagnosis typically relies on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MRI of the brain with contrast<\/strong> (preferred for sensitivity and surgical\/radiation planning)<\/li>\n\n\n\n<li><strong>CT<\/strong> when urgent evaluation is needed (e.g., acute neurological deterioration, suspected hemorrhage)<\/li>\n\n\n\n<li><strong>Metastasis biopsy and tissue diagnosis<\/strong> when imaging is atypical, when the primary tumor is unknown, or when pathology will change the treatment plan<\/li>\n\n\n\n<li><strong>Systemic staging<\/strong> is performed to assess the extent of extracranial disease and to confirm or identify the primary malignancy when needed. This typically includes contrast-enhanced CT of the chest, abdomen, and pelvis. <strong>PET-CT<\/strong> may be considered in selected cases, particularly when a more comprehensive assessment of metastatic spread is required for treatment planning or when conventional imaging is inconclusive. <strong>Tumor markers<\/strong> can support systemic evaluation in specific clinical contexts but are primarily used to monitor disease progression or treatment response rather than as standalone diagnostic tools.<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"680\" height=\"451\" src=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastases.jpg\" alt=\"Contrast-enhanced brain MRI showing multiple, well-circumscribed metastatic brain tumors in both hemispheres, appearing as bright lesions with surrounding edema.\" class=\"wp-image-10308\" srcset=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastases.jpg 680w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastases-300x199.jpg 300w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Brain-metastases-18x12.jpg 18w\" sizes=\"auto, (max-width: 680px) 100vw, 680px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Image: Contrast-enhanced brain MRI showing multiple, well-circumscribed metastatic brain tumors in both hemispheres, appearing as bright lesions with surrounding edema.<\/strong><\/p>\n\n\n\n<h2 id=\"when-primary-tumor-not-known\" class=\"wp-block-heading\">When Brain Metastases Are the First Sign of Cancer<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">If a brain metastasis is discovered before the primary cancer is known, the priority becomes:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>stabilizing urgent neurological risks (edema\/ICP, seizures, hemorrhage), and<\/li>\n\n\n\n<li>performing a structured systemic workup to identify the primary tumor and define a treatment strategy.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Differential Diagnosis of Brain Metastases<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary brain tumor (<a href=\"https:\/\/neurohirurgija.in.rs\/en\/glioblastoma-gbm\/\">glioblastoma<\/a>, <a href=\"https:\/\/neurohirurgija.in.rs\/en\/astrocytoma-brain-tumor\/\">astrocytoma<\/a>)<\/strong> \u2013 usually a single tumor that grows into surrounding brain tissue, not just pushing it aside<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/neurohirurgija.in.rs\/en\/cns-infections-brain-abscess-empyema\/\">Brain abscess<\/a> (infection)<\/strong> \u2013 can look similar on scans but is caused by bacteria or infection and often comes with fever<\/li>\n\n\n\n<li><strong><a href=\"https:\/\/neurohirurgija.in.rs\/en\/brain-lymphoma\/\">Primary CNS lymphoma<\/a><\/strong> \u2013 a type of cancer of immune cells in the brain, often located deep near the ventricles<\/li>\n\n\n\n<li><strong>Demyelinating disease (e.g., multiple sclerosis)<\/strong> \u2013 inflammatory lesions that can mimic tumors, especially in younger patients<\/li>\n\n\n\n<li><strong>Subacute stroke (infarction)<\/strong> \u2013 damaged brain tissue from reduced blood flow that can temporarily resemble a tumor on imaging<\/li>\n\n\n\n<li><strong>Radiation necrosis<\/strong> \u2013 tissue damage after previous radiotherapy that can look like tumor recurrence<\/li>\n\n\n\n<li><strong>Vascular lesions (cavernoma)<\/strong> \u2013 abnormal blood vessels that may appear as a mass but behave differently from tumors<\/li>\n\n\n\n<li><strong>Meningioma<\/strong> \u2013 usually a benign tumor arising from the brain covering (dura), often attached to the skull<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>In many patients, the diagnosis is relatively straightforward<\/strong> when there is a known primary cancer or when multiple lesions are present on imaging.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">How Neurosurgeons Decide on Surgery for Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">There is no single rule that applies to everyone. Decisions about surgery for brain metastases are <strong>never based on brain imaging alone<\/strong>. In real clinical practice, the <strong>expected prognosis of the primary cancer<\/strong>\u2014usually defined by the treating oncologist\u2014is one of the most important factors influencing whether surgery is recommended.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Modern guidelines describe surgery as a reasonable option in selected patients, particularly when a metastasis causes significant mass effect, rapid neurological deterioration, or when tissue diagnosis is required. However, neurosurgical intervention is generally considered meaningful <strong>only if the patient\u2019s overall cancer prognosis allows sufficient time to benefit from local brain control<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In most cases, the neurosurgeon relies on information provided by the oncology team regarding:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>the <strong>type of primary cancer<\/strong>,<\/li>\n\n\n\n<li>its <strong>biological aggressiveness<\/strong>,<\/li>\n\n\n\n<li>Status of the primary tumor, <strong>presence of other metastases, <\/strong>functional state of the affected organs, and <strong>comorbidities<\/strong>.<\/li>\n\n\n\n<li>available <strong>systemic treatment options<\/strong>,<\/li>\n\n\n\n<li>and the <strong>expected survival trajectory<\/strong> based on current oncological protocols.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A neurosurgical recommendation is therefore based on the combined picture of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expected prognosis of the primary cancer<\/strong>, as assessed by the treating oncologist<\/li>\n\n\n\n<li><strong>Neurological status and urgency<\/strong> (e.g., declining consciousness, focal deficits)<\/li>\n\n\n\n<li><strong>Tumor size and mass effect<\/strong>, including edema and risk of herniation<\/li>\n\n\n\n<li><strong>Tumor location and surgical risk<\/strong><\/li>\n\n\n\n<li><strong>Number of brain metastases<\/strong>, but never as the sole deciding factor<\/li>\n\n\n\n<li><strong>Extent and control of systemic disease<\/strong><\/li>\n\n\n\n<li><strong>Availability and timing of radiosurgery or radiotherapy<\/strong><\/li>\n\n\n\n<li><strong>Expected quality-of-life benefit<\/strong>, not merely radiological control<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">In practical terms, two patients with identical brain MRI findings may receive very different surgical recommendations if their <strong>primary cancer prognosis differs<\/strong>. Surgery may be appropriate in a patient with a controlled or treatable systemic malignancy, while the same procedure may offer little benefit in a patient with rapidly progressive, therapy-resistant disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Because so many variables influence whether and how to operate on one or more brain metastases,<strong> extensive neurosurgical experience is essential.<\/strong> It requires a high level of clinical judgment to correctly assess the combination of these factors, design a tailored surgical strategy, and execute the plan with precision.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 id=\"number-of-metastases-is-not-the-only-criterium-for-surgery\" class=\"wp-block-heading\">Why Metastasis Count Alone Does Not Decide Surgery<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The number of brain metastases matters\u2014but <strong>it does not determine the treatment plan by itself<\/strong>. Some patients may undergo surgery for multiple lesions if they are surgically accessible and if the expected neurological and functional benefit is high. Conversely, a single metastasis may not be operated on if it is located in a high-risk area, if radiosurgery offers equivalent local control with lower risk, or if systemic disease status makes surgery unlikely to improve overall outcome.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"why-two-neurosurgeons-two-opinions\" class=\"wp-block-heading\">Why Two Neurosurgeons May Recommend Different Plans \u2014 Operate or Not?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastasis care often involves <strong>clinical gray zones<\/strong> where more than one approach is medically reasonable. Differences in recommendations do not necessarily indicate an error, but reflect how complex decisions are made in real clinical practice.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Surgical Risk vs Expected Neurological Benefit<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">One neurosurgeon may prioritize <strong>maximal tumor removal<\/strong>, while another may focus on <strong>preserving neurological function<\/strong>, especially when the lesion is located in a high-risk area.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Availability and Role of Radiosurgery<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In some centers, stereotactic radiosurgery (SRS) is more readily integrated into treatment strategies, which may lead to recommendations that favor <strong>non-surgical approaches<\/strong> over open surgery.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Urgency of Symptom Progression<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If a patient is experiencing <strong>rapid neurological deterioration<\/strong>, surgery may be recommended more strongly. In more stable cases, less invasive options may be considered.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Interpretation of Systemic Disease and Prognosis<\/strong><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Decisions are heavily influenced by the <strong>primary cancer biology<\/strong>, <strong>extent of systemic disease<\/strong>, and <strong>expected survival<\/strong>. The same brain finding may be treated differently depending on the overall oncological context.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This variability is one of the main reasons why <strong>multidisciplinary evaluation<\/strong>\u2014and in selected cases, a <strong>second opinion<\/strong>\u2014can be valuable..<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"multidisciplinary-approach\" class=\"wp-block-heading\">Multidisciplinary Treatment Planning: Primary-Cancer Protocols First<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Brain metastases are not treated in isolation. In most cases, a multidisciplinary team plan is essential because:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>systemic cancer therapy is driven by the <strong>primary tumor type and molecular profile<\/strong>, and<\/li>\n\n\n\n<li>local brain control (surgery\/SRS\/WBRT) must be sequenced safely with systemic therapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Major guidelines emphasize that <strong>symptomatic brain metastases should receive local therapy<\/strong> and that deferral of local therapy for asymptomatic lesions should only occur when specifically recommended by evidence-based protocols.<\/p>\n\n\n\n<h2 id=\"treatment--modalities\" class=\"wp-block-heading\">Overview of Treatment Modalities for Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Most treatment plans combine two categories:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Symptom and risk control<\/strong> (edema\/ICP, seizures, hemorrhage risk)<\/li>\n\n\n\n<li><strong>Local control<\/strong> (surgery and\/or radiotherapy)<\/li>\n\n\n\n<li><strong>Systemic therapy<\/strong> (chosen according to primary tumor protocols and CNS activity)<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"symptomatic-treatment\" class=\"wp-block-heading\">Symptomatic Treatment of Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Symptomatic care may include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Corticosteroids<\/strong> to reduce edema and relieve symptoms from increased intracranial pressure (ICP)<\/li>\n\n\n\n<li><strong>Antiseizure therapy<\/strong> for <a href=\"https:\/\/neurohirurgija.in.rs\/en\/epilepsy-surgery-when-it-is-the-right-option\/\">patients with seizures<\/a> (and individualized decisions in others)<\/li>\n\n\n\n<li><strong>management of acute complications<\/strong> (e.g., hemorrhage, hydrocephalus, severe mass effect)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Evidence-based CNS guidelines recommend dexamethasone as the preferred steroid when corticosteroids are used, and emphasize tapering as quickly as clinically tolerated to reduce complications.<\/p>\n\n\n\n<h2 id=\"surgical-treatment\" class=\"wp-block-heading\">Surgical Treatment of Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Surgery may be used to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>rapidly relieve mass effect,<\/li>\n\n\n\n<li>obtain tissue diagnosis,<\/li>\n\n\n\n<li>achieve local control in selected cases (often combined with postoperative radiotherapy).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Guidelines describe surgery as most likely to benefit patients with <strong>large tumors causing mass effect<\/strong> and patients whose neurological function can be meaningfully improved.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Surgical removal of brain metastases is performed through a <strong><a href=\"https:\/\/neurohirurgija.in.rs\/en\/craniotomy-explained\/\">craniotomy<\/a><\/strong>, a procedure in which a small opening is made in the skull to access the brain. The goal of surgery is to safely reach the metastasis, relieve pressure on surrounding brain tissue, and remove the tumor when this can provide neurological or diagnostic benefit.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In many cases, brain metastases are <strong>well demarcated from normal brain tissue<\/strong>. Unlike infiltrative primary brain tumors, metastases often have a clear boundary, which makes surgical removal technically easier and safer in selected patients. When appropriate and safe, some surgeons also remove a <strong>thin margin of surrounding tissue<\/strong> to reduce the risk of local recurrence.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If anatomy and patient condition allow, <strong>more than one metastasis may be removed during the same operation<\/strong>, especially when lesions are accessible through the same surgical corridor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Surgery is performed <strong>under the operating microscope<\/strong>, which allows precise visualization and protection of normal brain structures. Modern neurosurgical procedures are supported by several advanced techniques, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neuronavigation<\/strong>, which helps the surgeon in the OR accurately locate the metastasis and plan the safest surgical trajectory<\/li>\n\n\n\n<li><strong>Preoperative imaging and surgical planning<\/strong>, including MRI-based planning tailored to each patient<\/li>\n\n\n\n<li><strong>Diffusion tensor imaging (tractography)<\/strong>, used when lesions are close to critical white matter pathways<\/li>\n\n\n\n<li><strong>Ultrasound guidance<\/strong>, which can help in OR to confirm tumor location and extent during surgery<\/li>\n\n\n\n<li><strong>Intraoperative neurophysiological monitoring<\/strong> (used selectively), particularly when lesions are near eloquent brain areas responsible for movement or speech<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These techniques help maximize tumor removal while minimizing the risk of neurological injury. The decision to operate, and the extent of resection, always depend on tumor location, neurological risk, and the overall treatment strategy defined together with the oncology team.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Read more about potential complications following craniotomy and open brain surgery on this&nbsp;<a href=\"https:\/\/neurohirurgija.in.rs\/en\/craniotomy-brain-surgery-complications\/\">page<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"400\" height=\"284\" src=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Craniotomy2.jpg\" alt=\"The image illustrates a craniotomy. Both the skin incision and the skull opening are performed within the hair-bearing area of the scalp. The dura is opened to expose the brain as part of the surgical approach to the tumor. After the procedure, the bone flap is secured and the scalp is reconstructed, ensuring no cosmetic defect remains after healing.\" class=\"wp-image-10304\" style=\"aspect-ratio:1.4084731774415407;width:542px;height:auto\" srcset=\"https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Craniotomy2.jpg 400w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Craniotomy2-300x213.jpg 300w, https:\/\/neurohirurgija.in.rs\/wp-content\/uploads\/2026\/01\/Craniotomy2-18x12.jpg 18w\" sizes=\"auto, (max-width: 400px) 100vw, 400px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Image: The image illustrates a craniotomy. Both the skin incision and the skull opening are performed within the hair-bearing area of the scalp. The dura is opened to expose the brain as part of the surgical approach to the tumor. After the procedure, the bone flap is secured and the scalp is reconstructed, ensuring no cosmetic defect remains after healing.<\/strong><\/p>\n\n\n\n<h2 id=\"radiotherapy\" class=\"wp-block-heading\">Stereotactic Radiosurgery and Radiotherapy in Brain Metastasis<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Radiotherapy plays a central role in the treatment of brain metastasis and can be used <strong>as a primary treatment, after surgery, or in combination with systemic therapy<\/strong>. The two main approaches\u2014<strong>stereotactic radiosurgery (SRS)<\/strong> and <strong>whole-brain radiotherapy (WBRT)<\/strong>\u2014differ fundamentally in indication, target volume, dose delivery, and neurocognitive impact.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Stereotactic Radiosurgery (SRS)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Stereotactic radiosurgery delivers a <strong>high dose of focused radiation<\/strong> precisely to one or more brain metastases while sparing surrounding normal brain tissue. Despite the term \u201csurgery,\u201d no incision is made.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>When SRS is used<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Limited number of brain metastases<\/strong> (commonly 1\u20134, and in selected patients a higher number, including cases with multiple lesions when cumulative tumor volume is low and systemic disease is well controlled)<\/li>\n\n\n\n<li>Lesions of relatively small size (typically \u22643\u20134 cm)<\/li>\n\n\n\n<li>Metastases located away from critical structures where safe dose delivery is possible<\/li>\n\n\n\n<li>Postoperative treatment of the surgical cavity after metastasis removal<\/li>\n\n\n\n<li>Patients with good neurological status and reasonable systemic disease control<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Typical dose concepts<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Single-fraction SRS: approximately <strong>18\u201324 Gy<\/strong> to each metastasis, depending on size and location<\/li>\n\n\n\n<li>Hypofractionated SRS (delivered over several sessions): used for larger lesions or lesions near critical structures<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The key advantage of SRS is <strong>high local control with substantially lower risk of cognitive decline<\/strong> compared with whole-brain approaches. Importantly, SRS treats <strong>only visible lesions<\/strong> and does <strong>not irradiate the entire brain<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Whole-Brain Radiotherapy (WBRT)<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Whole-brain radiotherapy delivers radiation to the <strong>entire brain<\/strong>, historically based on the assumption that microscopic metastases may already be present but not visible on imaging.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>When WBRT is considered<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Widespread intracranial disease<\/strong>, characterized by numerous metastases with a high cumulative tumor burden, where focal treatment would be impractical<\/li>\n\n\n\n<li><strong>Leptomeningeal metastasis<\/strong>, where diffuse CNS involvement precludes focal therapy<\/li>\n\n\n\n<li><strong>Rapid intracranial progression<\/strong>, particularly when new lesions develop faster than they can be safely managed with repeated focal treatments<\/li>\n\n\n\n<li><strong>Situations where repeated SRS is not feasible or has failed<\/strong>, due to cumulative dose constraints or declining neurological status<\/li>\n\n\n\n<li><strong>Selected palliative scenarios<\/strong>, especially in patients with poor performance status or limited expected survival<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Typical dose concepts<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Standard WBRT: <strong>30 Gy in 10 fractions<\/strong> or <strong>20 Gy in 5 fractions<\/strong>, depending on clinical context<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Do All Patients Need Whole-Brain Radiotherapy Because of Micrometastases?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. <strong>This is one of the most important shifts in modern practice.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Autopsy and imaging-based studies suggest that <strong>microscopic brain metastases likely exist in a substantial proportion of patients<\/strong> with systemic cancer. However, modern evidence shows that <strong>prophylactic irradiation of the entire brain does not improve overall survival<\/strong> in most patients with limited brain metastasis and significantly increases the risk of neurocognitive decline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As a result, current guidelines favor <strong>focal treatment (SRS) with close MRI surveillance<\/strong> rather than routine WBRT for patients with limited brain metastasis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Neurocognitive Toxicity and Brain-Sparing Strategies<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">WBRT is associated with a risk of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>memory impairment<\/li>\n\n\n\n<li>executive dysfunction<\/li>\n\n\n\n<li>reduced quality of life<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">To reduce this risk, modern WBRT techniques incorporate <strong>hippocampal avoidance<\/strong>, which spares the hippocampal region\u2014an area located deep within the <strong>temporal lobe<\/strong> (behind the temples) that is critical for memory formation. This technique is used when there is no metastasis near this structure. Pharmacologic strategies (e.g., memantine) may also be used to mitigate cognitive effects.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How the Choice Is Made in Practice<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The decision between SRS and WBRT is individualized and depends on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>number and size of brain metastases<\/li>\n\n\n\n<li>anatomical distribution<\/li>\n\n\n\n<li>risk of neurological deterioration<\/li>\n\n\n\n<li>patient age and baseline cognitive function<\/li>\n\n\n\n<li>expected survival based on primary cancer biology<\/li>\n\n\n\n<li>availability of close imaging follow-up<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Modern evidence-based recommendations, including those from <strong>ASTRO<\/strong>, emphasize <strong>maximizing neurological function and quality of life<\/strong>, not simply radiographic disease control.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Key Clinical Point<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Treating all visible brain metastases does not require treating the entire brain.<\/strong><br>In many patients, repeated focal treatment with SRS and careful MRI follow-up provides excellent neurological control while avoiding the long-term cognitive toxicity associated with whole-brain irradiation.<\/p>\n\n\n\n<h2 id=\"chemotherapy\" class=\"wp-block-heading\">Systemic Therapy for Brain Metastases (Expanded Clinical Overview)<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Systemic therapy for brain metastases is selected primarily according to the <strong>type and biology of the primary cancer<\/strong>, as well as the ability of available treatments to affect tumor cells within the central nervous system (CNS). Unlike local therapies (surgery or radiotherapy), systemic treatments are designed to control <strong>microscopic and macroscopic disease throughout the body<\/strong>, including potential disease beyond what is visible on imaging.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Main Categories of Systemic Therapy<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Depending on the primary tumor, systemic treatment protocols may include one or more of the following:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">1) Conventional Chemotherapy (Cytotoxic Agents)<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Traditional chemotherapy drugs (cytostatics) work by damaging rapidly dividing cancer cells. Examples include platinum-based agents, alkylating agents, and antimetabolites.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>BBB penetration:<\/strong><br>Most conventional chemotherapies have <strong>limited ability to cross an intact blood\u2013brain barrier (BBB)<\/strong>.<\/li>\n\n\n\n<li><strong>Effect in brain metastases:<\/strong><br>Their activity in the brain is often <strong>unpredictable and incomplete<\/strong>, which historically made the brain a \u201csanctuary site\u201d where cancer could progress despite good systemic control elsewhere.<\/li>\n\n\n\n<li><strong>Clinical implication:<\/strong><br>Chemotherapy alone is rarely sufficient for symptomatic brain metastases and is usually combined with local treatment.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2) Targeted Therapy<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Targeted therapies are drugs designed to block specific molecular pathways or mutations driving cancer growth (e.g., EGFR, ALK, ROS1, BRAF, HER2). A growth signal is sent either by surrounding normal cells or by the tumor cell itself in the form of signaling molecules. These molecules (growth factors or cytokines) bind to receptor proteins on the cell membrane, which then activate intracellular signaling pathways that transmit the message to the nucleus, promoting cell survival and division. This process is amplified in tumor cells because mutations in regulatory genes give them increased autonomy from normal tissue control.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Examples by tumor type:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Lung cancer: EGFR inhibitors, ALK inhibitors, ROS1 inhibitors<\/li>\n\n\n\n<li>Breast cancer: HER2-targeted agents<\/li>\n\n\n\n<li>Melanoma: BRAF and MEK inhibitors<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>BBB penetration:<\/strong><br>Many newer targeted agents have <strong>meaningful CNS penetration<\/strong>, especially compared with older drugs.<\/li>\n\n\n\n<li><strong>Clinical implication:<\/strong><br>In selected patients, targeted therapy can control <strong>both systemic disease and brain metastases<\/strong>, sometimes delaying or reducing the need for whole-brain radiotherapy.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">3) Immunotherapy<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Immunotherapy stimulates the patient\u2019s own immune system\u2014primarily T-lymphocytes, and in some cases antibody-mediated mechanisms\u2014to recognize and attack cancer cells.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Main classes:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Immune checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4 inhibitors)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>BBB considerations:<\/strong><br>Immunotherapy does <strong>not rely on direct drug penetration<\/strong> in the same way as chemotherapy. Activated immune cells can cross into the CNS and exert antitumor effects.<\/li>\n\n\n\n<li><strong>Clinical relevance:<\/strong><br>Particularly important in melanoma and certain lung cancers, immunotherapy has significantly improved survival and CNS disease control in selected patients.<\/li>\n\n\n\n<li><strong>Limitations:<\/strong><br>Response may be reduced in patients requiring high-dose steroids for brain edema.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">4) Cellular and Immune-Based Approaches (Emerging Therapies)<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">In selected cancers and clinical trials, more advanced immune strategies may be used:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cancer vaccines<\/strong> involve the administration of tumor-specific antigens that stimulate an active immune response, either humoral (antibody-mediated) or cellular (T-cell-mediated). These antigens may be derived from the patient\u2019s own tumor in personalized approaches or, more commonly, produced using genetic engineering to target antigens characteristic of a specific tumor type.<\/li>\n\n\n\n<li><strong>Adoptive T-cell therapy<\/strong> (e.g., tumor-infiltrating lymphocytes) involves collecting a patient\u2019s own T-lymphocytes, expanding or activating them in the laboratory, and reinfusing them to enhance the immune attack on the tumor.<\/li>\n\n\n\n<li><strong>Engineered immune-cell therapies<\/strong> use genetically modified immune cells, such as CAR-T cells, to specifically recognize and destroy cancer cells.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These therapies are <strong>not yet standard for most brain metastases<\/strong>, but they reflect ongoing efforts to overcome CNS immune resistance.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Blood\u2013Brain Barrier (BBB): Why Some Drugs Work and Others Do Not<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The blood\u2013brain barrier normally acts as a highly selective filter, protecting the brain from toxins\u2014but also limiting drug delivery.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Key clinical points:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In areas of active brain metastases, the BBB is often <strong>locally disrupted<\/strong>.<\/li>\n\n\n\n<li>This disruption creates a <strong>\u201cleaky barrier\u201d<\/strong> around the tumor, allowing some systemic drugs to reach metastatic tissue.<\/li>\n\n\n\n<li>However, <strong>BBB disruption is patchy and incomplete<\/strong>, meaning:\n<ul class=\"wp-block-list\">\n<li>Drug penetration varies between lesions<\/li>\n\n\n\n<li>Microscopic disease may remain protected<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Importantly, <strong>normal brain tissue away from metastases still has an intact BBB<\/strong>, limiting drug distribution.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This explains why systemic therapy may shrink some metastases while others persist or why new lesions can appear despite apparent response.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Why Systemic Therapy Alone Is Often Not Enough<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Despite major advances, current guidelines emphasize several limitations:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Systemic drugs usually <strong>act too slowly<\/strong> to relieve acute neurological emergencies (edema, mass effect, herniation).<\/li>\n\n\n\n<li>Drug concentrations in the brain may be <strong>insufficient or inconsistent<\/strong>.<\/li>\n\n\n\n<li>Steroids used to control brain edema can <strong>reduce the effectiveness of immunotherapy<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For these reasons, <strong>symptomatic brain metastases almost always require local treatment<\/strong> (surgery or radiotherapy), with systemic therapy serving as a complementary, not standalone, strategy.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 id=\"recurrent-metastases\" class=\"wp-block-heading\">Recurrent Brain Metastases<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Recurrent brain metastases are common, particularly in patients with longer survival due to effective systemic therapies. Management depends on prior treatments, lesion size and location, cumulative radiation dose, and overall neurological and systemic status. <strong>Repeat SRS<\/strong>, surgical resection, or a combination of focal therapies may be appropriate in selected cases, while <strong>WBRT<\/strong> is generally reserved for diffuse recurrence or situations where further focal treatment is no longer feasible.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">Key Clinical Perspective<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Systemic therapy plays a crucial role in controlling the underlying cancer and preventing further spread, but <strong>local brain treatment remains essential<\/strong> for preserving neurological function and preventing life-threatening complications. The optimal strategy integrates:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Primary cancer biology and available systemic therapies<\/li>\n\n\n\n<li>Neurological urgency and symptom burden<\/li>\n\n\n\n<li>Expected survival and quality-of-life benefit<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This integrated approach explains why treatment plans differ widely between patients\u2014and why multidisciplinary decision-making is essential.<\/p>\n\n\n\n<div style=\"border: 1px solid #ccc; border-radius: 12px; padding: 20px; margin-top: 40px; box-shadow: 0 2px 8px rgba(0,0,0,0.1); background-color: #f9f9f9;\">\n  <h2 id=\"request-brain-metastases-second-opinion\" style=\"margin-top: 0; color: #004466;\">\n    Request Brain Metastases Neurosurgery Consultation \u2014 24-Hour Review or Priority Option (Usually Within 3 Hours)\n  <\/h2>\n\n  <p>\n    When MRI or CT shows <strong>brain metastases (secondary brain tumors)<\/strong>, families often face urgent, high-stakes decisions:\n    whether surgery is needed, when stereotactic radiosurgery (SRS) is safer, when whole-brain radiotherapy (WBRT) is considered,\n    and how brain treatment should be sequenced with systemic cancer therapy.\n    <br><br>\n    An independent neurosurgical second opinion can help you understand the situation clearly, confirm whether the proposed plan is reasonable,\n    and explain what outcomes are realistic based on lesion size, location, edema\/ICP risk, neurological status, and the overall cancer context.\n  <\/p>\n\n  <ul style=\"padding-left: 0; margin-bottom: 20px; list-style: none;\">\n    <li style=\"position: relative; padding-left: 28px; margin: 8px 0;\">\n      <span style=\"position:absolute; left:0; top:0;\">\u2714<\/span>\n      Send a short message describing the diagnosis, symptoms (headache, seizures, weakness, speech problems, confusion), and what the MRI\/CT report says about the brain metastases\n    <\/li>\n\n    <li style=\"position: relative; padding-left: 28px; margin: 8px 0;\">\n      <span style=\"position:absolute; left:0; top:0;\">\u2714<\/span>\n      You\u2019ll receive a reply within 24 hours explaining if and how we can help in your specific brain metastases situation\n    <\/li>\n\n    <li style=\"position: relative; padding-left: 28px; margin: 8px 0;\">\n      <span style=\"position:absolute; left:0; top:0;\">\u2714<\/span>\n      <strong>Time-sensitive cases:<\/strong> if neurological status is worsening, hemorrhage\/major edema is present, hydrocephalus or midline shift is suspected, or doctors are urgently recommending surgery or radiation \u2014 write <strong>PRIORITY<\/strong> in your first message\n    <\/li>\n\n    <li style=\"position: relative; padding-left: 28px; margin: 8px 0;\">\n      <span style=\"position:absolute; left:0; top:0;\">\u2714<\/span>\n      If available MRI (DICOM) \/ CT images and hospital + oncology documentation can be reviewed once initial contact is established\n    <\/li>\n\n    <li style=\"position: relative; padding-left: 28px; margin: 8px 0;\">\n      <span style=\"position:absolute; left:0; top:0;\">\u2714<\/span>\n      During the consultation, we explain surgery vs SRS vs WBRT, expected neurological benefit, risks, and realistic outcomes \u2014 with up to 10 days of follow-up for brief questions\n    <\/li>\n  <\/ul>\n\n  <div style=\"margin-bottom: 15px;\">\n    <div style=\"font-weight: bold;\">\n      Consultation fees typically range from $180\u2013250, depending on case complexity and imaging findings.\n    <\/div>\n    <div style=\"font-weight: bold;\">\n      Secure payment by credit card, PayPal invoice (USD), or bank transfer.\n    <\/div>\n    <div style=\"font-size: 14px; color: #333; margin-top: 4px;\">\n      This is within the usual range for international specialist telehealth second opinions in neurosurgery.\n    <\/div>\n  <\/div>\n\n  <div style=\"display: flex; gap: 10px; flex-wrap: wrap;\">\n    <a href=\"https:\/\/wa.me\/381628534555\" style=\"background-color: #25D366; color: white; padding: 10px 16px; border-radius: 8px; text-decoration: none;\">\n      \ud83d\udcf1 WhatsApp Message\n    <\/a>\n    <a href=\"mailto:zkoja@yahoo.com\" style=\"background-color: #0073aa; color: white; padding: 10px 16px; border-radius: 8px; text-decoration: none;\">\n      \u2709 Email Us\n    <\/a>\n    <a href=\"https:\/\/m.me\/zeljko.kojadinovic.3\" style=\"background-color: #1877f2; color: white; padding: 10px 16px; border-radius: 8px; text-decoration: none;\">\n      \ud83d\udcac Messenger Chat\n    <\/a>\n  <\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"prognosis\" class=\"wp-block-heading\">Prognosis and Survival in Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Prognosis in patients with brain metastases is determined <strong>primarily by the biology of the primary cancer<\/strong>, not by brain imaging alone. Even with optimal local control of brain metastases, overall survival usually follows the natural course of the underlying malignancy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Across large clinical series, <strong>median survival after the diagnosis of brain metastases ranges from approximately 3 to 18 months<\/strong>, depending on the primary tumor and systemic disease control.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Primary Tumors with Relatively Longer Survival<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Patients with the following cancers tend to live <strong>longer<\/strong>, even after brain metastases develop, especially when modern systemic therapy is available:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breast cancer<\/strong>: often <strong>12\u201324 months or longer<\/strong>, particularly in HER2-positive and hormone-receptor-positive subtypes<\/li>\n\n\n\n<li><strong>Non-small cell lung cancer (NSCLC)<\/strong> with targetable mutations (EGFR, ALK): often <strong>10\u201320+ months<\/strong><\/li>\n\n\n\n<li><strong>Renal cell carcinoma<\/strong>: approximately <strong>8\u201315 months<\/strong> in selected patients<\/li>\n\n\n\n<li><strong>Melanoma<\/strong>: historically poor, but with immunotherapy <strong>6\u201312 months<\/strong>, with a subset of longer survivors<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Primary Tumors with Poorer Prognosis<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Some cancers exhibit more aggressive biology, where the disease progresses rapidly despite treatment:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Small-Cell Lung Cancer (SCLC):<\/strong> Typically <strong>3\u20136 months<\/strong>. While SCLC is highly sensitive to radiation (radiosensitive), it tends to recur quickly and spread aggressively throughout the body.<\/li>\n\n\n\n<li><strong>Triple-Negative Breast Cancer:<\/strong> Generally has a shorter survival window compared to other breast cancer subtypes due to a lack of targeted receptors.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Factors That Modify Survival<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Survival is shorter when there is:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>uncontrolled extracranial disease,<\/li>\n\n\n\n<li>poor neurological status at presentation,<\/li>\n\n\n\n<li>widespread intracranial involvement,<\/li>\n\n\n\n<li>lack of effective systemic therapy.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Survival is longer when:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>the primary cancer is biologically favorable or treatable,<\/li>\n\n\n\n<li>extracranial disease is controlled,<\/li>\n\n\n\n<li>effective local brain therapy (surgery and\/or stereotactic radiosurgery) is feasible,<\/li>\n\n\n\n<li>neurological function is preserved.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Key Clinical Point<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Successful removal or irradiation of all visible brain metastases does not mean the cancer has been cured.<\/strong><br>Local brain control improves neurological function and quality of life, but <strong>overall survival is usually dictated by the primary tumor and systemic disease<\/strong>, as assessed by the treating oncologist.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">In the following sections, we will discuss the <strong>specific characteristics of individual types of brain metastases.<\/strong><\/p>\n\n\n\n<h2 id=\"lung-cracinoma\" class=\"wp-block-heading\">Lung Cancer Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Lung cancer is the most common source of brain metastases, accounting for <strong>40\u201350% of all cases<\/strong>. While <strong>Non-Small Cell Lung Cancer (NSCLC)<\/strong> represents <strong>85%<\/strong> of lung cancers, <strong>Small-Cell Lung Cancer (SCLC)<\/strong>\u2014only <strong>15%<\/strong> of cases\u2014is responsible for a disproportionately high number of metastases, as over <strong>50%<\/strong> of SCLC patients will develop brain involvement. That is why SCLC is responsible for 25\u201330% of brain metastases of lung origin.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The treatment approach and operability differ fundamentally between these two types:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SCLC (Small-Cell):<\/strong> These are rarely operated on. Because SCLC is highly <strong>radiosensitive<\/strong> (responds rapidly to radiation) and typically presents with diffuse, microscopic spread, the standard of care is radiation (WBRT) or chemotherapy. <strong>Surgery is reserved only for exceptional cases<\/strong>, such as a single, large metastasis causing immediate life-threatening brain compression that does not respond to steroids. Despite local control, the prognosis remains poor (<strong>3\u20136 months<\/strong>) due to rapid systemic progression in other organs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>NSCLC (Non-Small Cell):<\/strong> These are the primary candidates for <strong>neurosurgical resection<\/strong>, especially when there is a single lesion causing mass effect. In cases with <strong>actionable mutations<\/strong> (EGFR, ALK, ROS1), survival often exceeds <strong>12\u201320 months<\/strong> due to modern drugs with high <strong>CNS activity<\/strong> (ability to penetrate the brain).<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"breast-carcinoma\" class=\"wp-block-heading\">Breast Cancer Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Breast cancer brain metastases are associated with <strong>relatively favorable survival<\/strong> compared with many other solid tumors. Account for 15-25% of all brain metastases.<br>Patients with <strong>HER2-positive and hormone-receptor-positive disease<\/strong> often live <strong>12\u201324 months or longer<\/strong>, reflecting effective modern systemic therapies with CNS activity.<br>Triple-negative breast cancer is associated with shorter survival, but outcomes still vary widely depending on systemic disease control.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"melanoma\" class=\"wp-block-heading\">Melanoma Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Melanoma is now one of the primary cancers with the best long-term outcomes in selected patients with brain metastases. Account for 5-20% of all brain metastases. Historically, the prognosis was poor, with survival measured in only <strong>6\u201312 months<\/strong>. However, a major breakthrough in <strong>immunotherapy<\/strong> and <strong>targeted therapy<\/strong> has shifted the paradigm: as systemic treatments allow patients to live longer, we are seeing an increasing incidence of brain metastases\u2014occurring in up to <strong>40\u201350%<\/strong> of patients with advanced melanoma.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Due to this improved systemic prognosis, neurosurgical strategy has become more aggressive. We now frequently perform <strong>surgical resections even for multiple metastases<\/strong>, especially when combined with <strong>Stereotactic Radiosurgery (SRS)<\/strong> for smaller, deep-seated lesions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">While long-term, durable survival is now realistically achievable in a subset of patients, certain factors still limit the outcome:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Steroid Dependence:<\/strong> Prognosis is worse in patients requiring high-dose steroids (which can interfere with immunotherapy).<\/li>\n\n\n\n<li><strong>Disease Extent:<\/strong> Outcomes are more guarded with extensive intracranial disease or <strong>leptomeningeal involvement<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Despite these challenges, melanoma is no longer considered a disease of uniformly poor prognosis; for many, it has become a manageable condition with the right combination of surgery and modern systemic therapy.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"renal-cell-carcinoma\" class=\"wp-block-heading\">Renal Cell Carcinoma Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Renal cell carcinoma brain metastases are often <strong>hypervascular and prone to hemorrhage<\/strong>. Account for 5-10% of all brain metastases.<br>Despite relative radioresistance, patients with limited brain disease and controlled systemic cancer may achieve <strong>meaningful survival<\/strong>, commonly in the range of <strong>8\u201315 months or longer<\/strong> when surgery or stereotactic radiosurgery is feasible.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"colorectal-cancer\" class=\"wp-block-heading\">Colorectal Cancer Brain Metastases<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Colorectal cancer brain metastases usually occur <strong>late in the disease course<\/strong> and are frequently associated with widespread systemic disease. Account for 3-5% of all brain metastases.<br>As a result, prognosis is often <strong>less favorable<\/strong>, with survival commonly measured in months, although selected patients with limited disease and good systemic control may do better.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"unknown-primary-tumor\" class=\"wp-block-heading\">Brain Metastases from an Unknown Primary Tumor<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In a substantial proportion of patients, brain metastases are diagnosed <strong>before the primary tumor is identified<\/strong>. Account for 20-30% of all brain metastases.<br>Prognosis in these cases depends on how quickly the primary cancer can be identified and whether it represents a <strong>biologically treatable tumor<\/strong>. Outcomes vary widely and cannot be predicted from brain imaging alone.<\/p>\n\n\n\n<h2 id=\"faq-brain-metastasis\" style=\"margin-top: 14px;\">Frequently Asked Questions About Brain Metastasis<\/h2>\n\n<div class=\"faq-accordion\" style=\"margin:32px 0;\">\n  <style>\n    .faq-accordion details {\n      border: 1px solid #e3e8ef;\n      border-radius: 10px;\n      background: #f8fafc;\n      padding: 12px 16px;\n      margin: 10px 0;\n    }\n\n    .faq-accordion summary {\n      cursor: pointer;\n      list-style: none;\n      display: flex;\n      align-items: center;\n      justify-content: space-between;\n      gap: 12px;\n    }\n\n    .faq-accordion summary::-webkit-details-marker {\n      display: none;\n    }\n\n    .faq-accordion summary::after {\n      content: \"\uff0b\";\n      font-size: 1.2em;\n      font-weight: 700;\n      color: #0b3a5e;\n      flex-shrink: 0;\n    }\n\n    .faq-accordion details[open] summary::after {\n      content: \"\u2212\";\n    }\n\n    .faq-accordion .answer {\n      margin-top: 10px;\n      color: #0f172a;\n      line-height: 1.6;\n    }\n\n    .faq-accordion .answer p {\n      margin: 0 0 10px 0;\n    }\n\n    .faq-accordion .answer p:last-child {\n      margin-bottom: 0;\n    }\n  <\/style>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is a brain metastasis?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>A brain metastasis is a tumor in the brain that has spread from cancer elsewhere in the body. It is also called a secondary brain tumor because it did not start from brain tissue itself. Common primary sources include lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Brain metastases behave differently from primary brain tumors because they are part of a systemic cancer process. Treatment therefore depends not only on the brain lesion, but also on the type of primary cancer, extracranial disease control, neurological symptoms, number and size of lesions, available systemic therapy, and the patient\u2019s overall functional condition.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Is brain metastasis the same as secondary brain cancer?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes. Brain metastasis is commonly described as secondary brain cancer because the cancer started somewhere else and then spread to the brain. This is different from primary brain cancer, which begins in the brain itself. For example, lung cancer that spreads to the brain is still lung cancer biologically, not a primary brain tumor. This distinction matters because systemic treatment is chosen according to the original cancer type and its molecular profile. Local brain treatment such as surgery, stereotactic radiosurgery, or whole-brain radiotherapy may control the brain disease, but overall prognosis is often determined by the behavior of the primary cancer and extracranial disease.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Which cancers most commonly spread to the brain?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>The cancers that most commonly spread to the brain are lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. Lung cancer is the most frequent source overall, while melanoma has a strong biological tendency to involve the brain during advanced disease. Breast cancer brain metastases are especially important in HER2-positive, hormone-receptor-positive, and triple-negative subtypes, because prognosis and systemic treatment options differ between these groups. Renal cell carcinoma metastases are often vascular and may bleed. Colorectal cancer brain metastases usually occur later in the disease course. Because each primary cancer behaves differently, brain metastasis treatment must be individualized rather than based on brain MRI alone.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can brain metastasis be the first sign of cancer?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes. In some patients, a brain metastasis is discovered before the primary cancer is known. This may happen when a person develops headache, seizure, weakness, speech problems, confusion, or gait imbalance and brain imaging shows one or more suspicious lesions. In that situation, urgent neurological stabilization and a structured systemic workup are both important. MRI of the brain helps define the lesion pattern, while CT chest, abdomen, and pelvis, PET-CT in selected cases, laboratory tests, and tissue diagnosis may be needed to identify the primary cancer. If imaging is atypical or the primary tumor is unknown, biopsy or surgical removal may also provide the diagnosis needed for treatment planning.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What symptoms can brain metastases cause?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Brain metastases can cause headache, nausea, vomiting, seizures, weakness, speech difficulty, visual symptoms, imbalance, confusion, memory problems, personality change, or reduced consciousness. Symptoms depend more on location, swelling, bleeding, and pressure effects than on the primary cancer type alone. A small metastasis in the cerebellum or near cerebrospinal fluid pathways may cause severe symptoms, while a larger lesion in a less critical area may progress more slowly. Sudden worsening may occur if the metastasis bleeds, causes acute hydrocephalus, produces severe edema, or leads to raised intracranial pressure. New neurological symptoms in a cancer patient should therefore be evaluated urgently.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Why can a small brain metastasis cause severe symptoms?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>A small brain metastasis can cause severe symptoms because the problem is not tumor size alone. Many metastases disrupt the blood\u2013brain barrier and produce vasogenic edema, meaning fluid leaks into surrounding brain tissue. This swelling can compress nearby pathways, increase intracranial pressure, shift brain structures, or obstruct cerebrospinal fluid circulation. In tight spaces such as the posterior fossa, even a modest cerebellar metastasis can compress the brainstem or block CSF pathways and cause acute hydrocephalus. Some metastases also bleed, especially melanoma and renal cell carcinoma metastases. Therefore, symptom severity depends on location, edema, hemorrhage, mass effect, and neurological reserve, not only on lesion diameter.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Are brain metastases usually single or multiple?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Brain metastases may be single or multiple. Many patients have multiple brain metastases at diagnosis because metastatic disease reflects systemic cancer cells spreading through the bloodstream. However, a single brain metastasis is also common and may raise important treatment questions, especially when the primary cancer is controlled or when tissue diagnosis is needed. The number of metastases matters, but it does not decide treatment by itself. A single lesion may be treated with surgery or stereotactic radiosurgery, while selected patients with several lesions may still benefit from focal treatment if the total tumor volume is limited and systemic disease is reasonably controlled. Location, symptoms, edema, prognosis, and available systemic therapy are equally important.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">How is brain metastasis diagnosed?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Brain metastasis is usually diagnosed with contrast-enhanced MRI of the brain, which is more sensitive than CT for detecting small or multiple lesions. CT may be used urgently when there is sudden neurological deterioration, suspected hemorrhage, hydrocephalus, or raised intracranial pressure. Diagnosis is often straightforward when a patient has known systemic cancer and MRI shows typical multiple enhancing lesions. Tissue diagnosis may be needed when the primary cancer is unknown, imaging is atypical, or pathology will change treatment. Systemic staging is also important and may include CT chest, abdomen, and pelvis, PET-CT in selected cases, laboratory tests, and biopsy from the most informative site.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Is surgery always required for brain metastasis?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>No. Surgery is not required for every brain metastasis. Many brain metastases are treated with stereotactic radiosurgery, whole-brain radiotherapy, systemic therapy, steroids, seizure treatment, or careful sequencing of several approaches. Surgery is usually considered when a metastasis is large, causes significant mass effect, produces rapid neurological deterioration, bleeds, blocks cerebrospinal fluid pathways, or when tissue diagnosis is needed. The decision also depends on the primary cancer prognosis, extracranial disease control, neurological status, number and location of lesions, and expected quality-of-life benefit. Some patients benefit greatly from surgery, while others are better treated with non-surgical local therapy or systemic treatment.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">When is surgery recommended for brain metastasis?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Surgery for brain metastasis is most often recommended when local brain control can meaningfully improve neurological function, reduce pressure, obtain diagnosis, or prevent rapid deterioration. It is especially considered for large symptomatic metastases, lesions causing severe edema or midline shift, cerebellar metastases threatening the brainstem or causing hydrocephalus, hemorrhagic metastases with mass effect, or a single accessible lesion when diagnosis is uncertain. Surgery is more likely to help when the patient has reasonable functional status and the systemic cancer prognosis allows time to benefit from brain treatment. It is less helpful when disease is widespread, neurological damage is irreversible, or systemic cancer is rapidly progressing despite treatment.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can multiple brain metastases be surgically removed?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes, but only in selected patients. Multiple brain metastases can sometimes be surgically removed when several lesions are accessible, symptomatic, causing mass effect, or reachable through the same surgical corridor. Surgery may also be used for the dominant lesion while smaller lesions are treated with stereotactic radiosurgery. However, multiple metastases do not automatically mean surgery is useful, and a single metastasis does not automatically mean surgery is required. The key questions are whether surgery will improve neurological function, relieve pressure, provide diagnosis, reduce steroid dependence, or allow safer further oncological treatment. The decision must include systemic cancer status, expected survival, neurological risk, and alternatives such as SRS or WBRT.<\/p>\n    <\/div>\n  <\/details>\n\n<details>\n  <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What are the specific risks and complications of brain metastasis surgery?<\/h3><\/summary>\n  <div class=\"answer\">\n    <p>The risks of brain metastasis surgery depend mainly on the lesion\u2019s size, location, surrounding edema, blood supply, and relationship to functional brain areas, major arteries, veins, cranial nerves, and cerebrospinal fluid pathways. Possible complications include bleeding, postoperative hematoma, brain swelling, seizures, infection, meningitis, cerebrospinal fluid leakage, stroke, venous infarction, hydrocephalus, wound-healing problems, and the need for additional surgery.<\/p>\n\n    <p>New neurological deficits may include weakness or paralysis, speech or language impairment, visual field loss, sensory disturbance, memory or cognitive decline, balance problems, cranial nerve dysfunction, or reduced consciousness. Some deficits are temporary and improve as postoperative swelling resolves, while others may be permanent if critical cortex, white-matter pathways, arteries, veins, or cranial nerves are affected. In highly vascular metastases, particularly those from renal cell carcinoma, melanoma, or certain lung cancers, the risk of intraoperative bleeding may be greater. A broader explanation is available on our <a href=\"https:\/\/neurohirurgija.in.rs\/en\/craniotomy-brain-surgery-complications\/\">craniotomy and brain surgery complications page<\/a>.<\/p>\n  <\/div>\n<\/details>\n\n<details>\n  <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can brain metastases bleed and cause sudden neurological deterioration?<\/h3><\/summary>\n  <div class=\"answer\">\n    <p>Yes. Some brain metastases have a greater tendency to bleed, particularly those originating from melanoma, renal cell carcinoma, choriocarcinoma, and certain lung cancers. Bleeding may occur inside the tumor or into the surrounding brain and can suddenly increase mass effect and intracranial pressure.<\/p>\n\n    <p>Symptoms may include a sudden severe headache, vomiting, weakness or paralysis on one side, speech disturbance, seizures, confusion, reduced consciousness, or rapid neurological collapse. Acute hemorrhage may transform a previously stable situation into a neurosurgical emergency. Urgent CT or MRI is required to determine the extent of bleeding, edema, brain shift, and whether emergency surgery, intensive monitoring, or another treatment is necessary.<\/p>\n  <\/div>\n<\/details>\n\n<details>\n  <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Why can Dexamethasone rapidly improve symptoms without treating the brain metastasis itself?<\/h3><\/summary>\n  <div class=\"answer\">\n    <p>Dexamethasone reduces vasogenic brain edema, which is swelling caused by leakage of fluid from abnormal blood vessels around the metastasis. This swelling may be responsible for much of the headache, weakness, speech difficulty, confusion, nausea, or reduced consciousness experienced by the patient.<\/p>\n\n    <p>Symptoms can improve within hours or days because reducing edema lowers intracranial pressure and relieves compression of nearby brain tissue. However, Dexamethasone does not remove or destroy the metastasis itself. The underlying tumor remains and usually still requires local treatment such as surgery or stereotactic radiosurgery, together with systemic cancer therapy when appropriate. Steroids should be reduced to the lowest effective dose because prolonged use can cause infection, muscle weakness, high blood sugar, stomach problems, mood changes, and other complications.<\/p>\n  <\/div>\n<\/details>\n\n<details>\n  <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can new brain metastases appear after surgery or stereotactic radiosurgery?<\/h3><\/summary>\n  <div class=\"answer\">\n    <p>Yes. Surgery and stereotactic radiosurgery provide local control of the treated metastasis or metastases, but they do not always prevent new tumor cells from reaching other parts of the brain. The underlying systemic cancer may continue to release malignant cells into the bloodstream, leading to new CNS seeding over time.<\/p>\n\n    <p>For this reason, patients require regular follow-up MRI even when the treated lesions are completely removed or remain controlled. New metastases may be treated with additional stereotactic radiosurgery, surgery, whole-brain radiotherapy in selected cases, or systemic therapy with CNS activity. The risk of new lesions depends on the biology of the primary cancer, systemic disease control, previous treatments, and the duration of survival after the initial brain treatment.<\/p>\n  <\/div>\n<\/details>\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is the difference between surgery, stereotactic radiosurgery, and whole-brain radiotherapy for brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Surgery physically removes a brain metastasis through a craniotomy and is most useful for large, symptomatic, hemorrhagic, or diagnostically uncertain lesions. Stereotactic radiosurgery (SRS) is focused radiation delivered precisely to one or more visible metastases without an incision; it is often used for smaller lesions or after surgery to treat the surgical cavity. Whole-brain radiotherapy (WBRT) treats the entire brain and is mainly used when there are numerous metastases, diffuse intracranial disease, leptomeningeal spread, or when repeated focal treatment is not feasible. The best choice depends on lesion size, number, location, symptoms, cognitive risk, systemic cancer status, expected survival, and treatment goals.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">When is stereotactic radiosurgery (SRS) used for brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Stereotactic radiosurgery (SRS) is commonly used for brain metastases when lesions are relatively small, well-defined, and safely targetable with focused radiation. It may be used for one metastasis, several metastases, or selected patients with more lesions when total tumor volume is limited and close MRI follow-up is possible. SRS is also frequently used after surgical removal to treat the resection cavity and reduce local recurrence risk. Its main advantage is high local control while avoiding the broader cognitive risks of whole-brain radiotherapy. SRS is less suitable when a lesion is very large, causing dangerous mass effect, bleeding with compression, obstructing CSF pathways, or located where safe dose delivery is difficult.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">When is whole-brain radiotherapy (WBRT) used for brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Whole-brain radiotherapy (WBRT) is used when brain metastases are widespread, when there are many lesions with high total tumor burden, when leptomeningeal disease is present, or when repeated focal treatment with surgery or SRS is no longer feasible. It may also be used in selected palliative situations when the goal is symptom control rather than durable local control of a few lesions. WBRT treats visible and microscopic disease throughout the brain, but it carries a higher risk of memory and cognitive decline than focal approaches. Modern strategies such as hippocampal avoidance and memantine may reduce cognitive toxicity in selected patients. The decision depends on disease extent, expected survival, cognition, and treatment goals.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is the life expectancy when cancer spreads to the brain?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Life expectancy when cancer spreads to the brain varies widely and cannot be predicted from brain MRI alone. Across large clinical series, median survival after brain metastasis diagnosis may range from only a few months to more than a year, and in selected patients longer. The most important factors are the type of primary cancer, molecular profile, extracranial disease control, neurological status, number and size of brain metastases, availability of surgery or stereotactic radiosurgery, response to systemic therapy, and overall functional condition. Some patients with controlled systemic disease and effective modern treatment live for years, while others deteriorate quickly because of aggressive systemic cancer, diffuse CNS spread, infection, thrombosis, or metabolic failure.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can patients die even when all visible brain metastases are controlled?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes. Patients can deteriorate or die even when all visible brain metastases are controlled on MRI. Local brain control is very valuable because it can reduce pressure, prevent neurological crises, improve seizures, and preserve function. However, it does not mean the underlying cancer has been cured. Survival may still be limited by systemic cancer progression, microscopic spread that is not visible on imaging, leptomeningeal disease, new CNS seeding, paraneoplastic neurological syndromes, blood clots, infection, metabolic failure, treatment toxicity, or organ failure. This is why brain metastasis care must combine local brain treatment with systemic oncology planning and realistic prognosis discussion.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Does the primary cancer type change brain metastasis treatment and life expectancy?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes. The primary cancer type strongly changes both brain metastasis treatment and life expectancy. Lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer can all spread to the brain, but they behave differently and respond to different systemic treatments. Non-small cell lung cancer with EGFR or ALK mutations may respond to CNS-active targeted therapy. HER2-positive breast cancer may have longer survival with modern systemic treatment. Melanoma outcomes have improved with immunotherapy and targeted therapy. Renal cell carcinoma metastases may bleed and often need surgery or SRS when limited. Small-cell lung cancer is usually radiosensitive but aggressive. Therefore, brain treatment must be integrated with primary-cancer biology.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is different about lung cancer brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Lung cancer is the most common source of brain metastases, but treatment and prognosis differ between non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC brain metastases may be treated with surgery, stereotactic radiosurgery, radiotherapy, and systemic therapy, especially when targetable mutations such as EGFR, ALK, or ROS1 are present. Some newer drugs have meaningful CNS activity and can improve disease control. SCLC is usually highly radiosensitive but biologically aggressive, often spreading early and diffusely. Surgery for SCLC brain metastasis is uncommon and reserved for exceptional cases such as a single large lesion causing dangerous mass effect. Prognosis depends strongly on systemic disease control and treatment response.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is different about breast cancer brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Breast cancer brain metastases have a wide range of outcomes because breast cancer includes biologically different subtypes. HER2-positive and hormone-receptor-positive cancers may have better prognosis when modern systemic therapies are effective and extracranial disease is controlled. Triple-negative breast cancer usually behaves more aggressively and may have a shorter survival window, although individual outcomes vary. Treatment may include surgery for large or symptomatic lesions, stereotactic radiosurgery for limited lesions, whole-brain radiotherapy in diffuse disease, and systemic therapy chosen according to receptor status and prior treatment. Prognosis depends on subtype, number and size of brain metastases, extracranial disease, functional status, and whether effective CNS-active systemic options are available.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is different about melanoma brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Melanoma brain metastases are different because melanoma has a strong tendency to spread to the brain and some lesions may bleed. Historically, prognosis was poor, but outcomes have improved substantially for selected patients because of immunotherapy and targeted therapy, especially when disease is limited and treatment response is good. Surgery may be used for large symptomatic or hemorrhagic lesions, while stereotactic radiosurgery is often used for smaller or multiple lesions. A key issue is steroid dependence: high-dose steroids may be necessary for brain edema, but they can reduce the effectiveness of immunotherapy. Prognosis is best when neurological symptoms are controlled, steroid needs are low, systemic disease is treatable, and focal brain therapy is feasible.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">What is different about renal cell carcinoma brain metastases?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Renal cell carcinoma brain metastases are often hypervascular, meaning they contain many fragile blood vessels, and they may have a higher tendency to hemorrhage. This can make sudden neurological worsening possible and may influence surgical planning. Renal cell carcinoma has historically been considered relatively resistant to conventional whole-brain radiotherapy, so focal treatments such as surgery and stereotactic radiosurgery are often important when brain disease is limited and systemic condition allows treatment. Modern systemic therapies have improved outcomes in selected patients, but brain treatment still depends on lesion size, location, bleeding risk, edema, neurological symptoms, extracranial disease control, and expected survival. In suitable cases, local treatment can preserve function and quality of life.<\/p>\n    <\/div>\n  <\/details>\n\n  <details>\n    <summary style=\"cursor:pointer;list-style:none;\"><h3 style=\"display:inline;font-size:1.05em;font-weight:700;margin:0;color:#003366;\">Can an online neurosurgical second opinion help with brain metastasis treatment decisions?<\/h3><\/summary>\n    <div class=\"answer\">\n      <p>Yes. An online neurosurgical second opinion can help when treatment decisions for brain metastasis are unclear, urgent, or contradictory. It is especially useful when surgery is being proposed or declined, when several lesions are present, when SRS or WBRT is being discussed, when prognosis estimates differ, or when neurological worsening may be caused by edema, hemorrhage, hydrocephalus, mass effect, leptomeningeal disease, or systemic cancer progression. MRI or CT images, oncology records, pathology, current neurological status, and systemic staging information can be reviewed to explain whether surgery, SRS, WBRT, systemic therapy, or symptom-focused treatment is most realistic. The goal is to clarify expected neurological benefit, risks, timing, and quality-of-life implications.<\/p>\n    <\/div>\n  <\/details>\n\n<\/div>\n\n\n\n<div class=\"external-patient-links\" style=\"margin:20px 0; padding:14px 16px; border:1px solid #e3e8ef; border-radius:10px; background:#f8fafc;\">\n  <p style=\"margin:0 0 10px 0; font-weight:700; color:#0b3a5e;\">\n    Trusted Resources for Patients and Families (Brain Metastases)\n  <\/p>\n\n  <ul style=\"margin:0; padding-left:18px; line-height:1.7;\">\n\n    <li>\n      <a href=\"https:\/\/www.cancer.gov\/types\/brain\/patient\/metastatic-brain-treatment-pdq\"\n         target=\"_blank\" rel=\"noopener\" \n         style=\"color:#005c99; text-decoration:underline;\">\n        National Cancer Institute (NCI) \u2014 Metastatic Brain Tumors Patient Guide\n      <\/a>\n    <\/li>\n\n    <li>\n      <a href=\"https:\/\/www.abta.org\/tumor_types\/metastatic-brain-tumors\/\"\n         target=\"_blank\" rel=\"noopener\" \n         style=\"color:#005c99; text-decoration:underline;\">\n        American Brain Tumor Association (ABTA) \u2014 Metastatic Brain Tumor Overview\n      <\/a>\n    <\/li>\n\n    <li>\n      <a href=\"https:\/\/www.cancer.net\/cancer-types\/brain-tumor\/metastatic-brain-tumors\"\n         target=\"_blank\" rel=\"noopener\" \n         style=\"color:#005c99; text-decoration:underline;\">\n        Cancer.Net (ASCO) \u2014 Understanding Brain Metastases: Symptoms and Care\n      <\/a>\n    <\/li>\n\n    <li>\n      <a href=\"https:\/\/www.mskcc.org\/cancer-care\/types\/brain-tumors-metastatic\/understanding-brain-metastases\"\n         target=\"_blank\" rel=\"noopener\" \n         style=\"color:#005c99; text-decoration:underline;\">\n        Memorial Sloan Kettering (MSKCC) \u2014 Brain Metastases: Frequently Asked Questions\n      <\/a>\n    <\/li>\n\n  <\/ul>\n\n  <p style=\"margin:12px 0 0 0; font-size:0.95em; color:#334155;\">\n    These external resources provide general educational information and do not replace individualized medical assessment or an expert neurosurgical consultation.\n  <\/p>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Author: Dr. Zeljko Kojadinovic, MD, PhD \u2014 Neurosurgeon and Pain Management Specialist Specialized Experience: 30 years of clinical expertise in neurosurgery. Last medically reviewed: May 28, 2026 Who This Brain Metastases Page Is For This page is intended for patients diagnosed with brain metastases (secondary brain tumors) and for family members seeking a clear, medically [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_titles_title":"Brain Metastases \u2014 Surgical Decisions, Treatment & Prognosis","_seopress_titles_desc":"Neurosurgeon expert overview of brain metastases: diagnosis, symptoms, surgical and radiation treatment options, prognosis, and second opinion guidance.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-10610","page","type-page","status-publish","hentry"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/pages\/10610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/comments?post=10610"}],"version-history":[{"count":62,"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/pages\/10610\/revisions"}],"predecessor-version":[{"id":15160,"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/pages\/10610\/revisions\/15160"}],"wp:attachment":[{"href":"https:\/\/neurohirurgija.in.rs\/en\/wp-json\/wp\/v2\/media?parent=10610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}